Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 39, 4816-4822, December 1, 1979]
© 1979 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, L. H.
Right arrow Articles by Krueger, W. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L. H.
Right arrow Articles by Krueger, W. C.

Comparative Biological and Biochemical Effects of Nogalamycin and Its Analogs on L1210 Leukemia1

Li H. Li2, Sandra L. Kuentzel, Lana L. Murch, Loraine M. Pschigoda and William C. Krueger

Research Laboratories, The Upjohn Company, Kalamazoo, Michigan 49001

Nogalamycin, an anthracycline antibiotic, was active against L1210 leukemia in vitro and in vivo. Several new analogs synthesized recently were more active against P388 leukemia, L1210 leukemia, and/or B16 melanoma than was nogalamycin. This study compares the biological and biochemical effects of these compounds on L1210 leukemic cells. Compounds containing the nogalose moiety inhibited RNA synthesis more than DNA synthesis. Nogalamycin (50% inhibitory dose, 0.4 nmol/ml) and dis-nogamycin (50% inhibitory dose, 0.5 nmol/ml) were much more inhibitory towards RNA synthesis than was dis-nogalamycinic acid (50% inhibitory dose, 3.6 nmol/ml). These results paralleled those of cell growth inhibition as well as drug-DNA interaction as measured by circular dichroism and thermal melting of DNA, suggesting that the inhibition of RNA synthesis by these compounds was the result of a major biochemical lesion, probably mediated through the interaction with DNA. With the 7-alkyl analogs, RNA synthesis again was generally inhibited more than DNA synthesis. The dis isomers, i.e., 7-dis-O-methylnogalarol, 7-dis-O-methylnogarol, and 7-dis-O-ethylnogarol, inhibited RNA synthesis more than did the corresponding con isomers. This phenomenon correlated well with stronger interaction between the dis isomers and DNA. However, the con isomers were generally more inhibitory towards L1210 cell growth. By and large, the biochemical effects observed with the con isomers, particularly 7-con-O-methylnogarol, could not account for their biological activities which appear to be mediated through some mechanism other than their interaction with DNA. The significance of these findings is discussed in terms of drug development.

1 This investigation was supported in part by Contract N01-CM-43753, Division of Cancer Treatment, National Cancer Institute, NIH, Department of Health, Education, and Welfare.

2 To whom requests for reprints should be addressed.

Received 4/ 4/79. Accepted 8/21/79.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
W. B.T. Cruse, P. Saludjian, Y. Leroux, G. Leger, D. El Manouni, and T. Prange
A Continuous Transition from A-DNA to B-DNA in the 1:1 Complex between Nogalamycin and the Hexamer dCCCGGG
J. Biol. Chem., June 28, 1996; 271(26): 15558 - 15567.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1979 by the American Association for Cancer Research.